Edition:
India

Anixa Biosciences Inc (ANIX.OQ)

ANIX.OQ on NASDAQ Stock Exchange Capital Market

3.70USD
1:30am IST
Change (% chg)

$0.15 (+4.23%)
Prev Close
$3.55
Open
$3.55
Day's High
$3.70
Day's Low
$3.55
Volume
4,293
Avg. Vol
12,609
52-wk High
$6.86
52-wk Low
$3.30

Latest Key Developments (Source: Significant Developments)

Anixa Biosciences Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Wednesday, 12 Jun 2019 

June 11 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $100 MILLION – SEC FILING.  Full Article

Anixa Biosciences Announces Completion Of Pre-Sub Meeting With FDA
Wednesday, 19 Dec 2018 

Dec 19 (Reuters) - Anixa Biosciences Inc ::ANIXA BIOSCIENCES ANNOUNCES COMPLETION OF PRE-SUB MEETING WITH FDA FOR ITS CCHEK CANCER DIAGNOSTIC TEST.ANIXA BIOSCIENCES INC - ANNOUNCED THAT IT COMPLETED A PRE-SUBMISSION (PRE-SUB) MEETING WITH US FDA ON DECEMBER 17, 2018..ANIXA BIOSCIENCES INC - DISCUSSION FOCUSED ON USING CCHEK FOR PROSTATE CANCER TESTING, AS PROSTATE CANCER WILL BE FIRST COMMERCIAL APPLICATION..  Full Article

Itus Corporation Terminates At-The-Market Offering
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Itus Corp ::ITUS CORPORATION TERMINATES AT-THE-MARKET OFFERING.‍TERMINATED ITS AT-THE-MARKET EQUITY PROGRAM WITH B. RILEY FBR INC​.  Full Article

Itus enters into 2-year collaboration agreement
Thursday, 23 Nov 2017 

Nov 22 (Reuters) - Itus Corp ::Itus Corp - ‍on Nov 17, co, through unit entered into a 2 -year collaboration agreement with H. Lee Moffitt Cancer Center And Research Institute​.Itus - ‍ deal to advance toward human clinical testing car-t technology licensed by unit from Wistar Institute aimed initially at treating ovarian cancer​.Itus Corp says unit of co to pay Moffitt $1.16 million over two years for its efforts in collaboration - SEC filing.Itus Corp - unit to work with researchers at Moffitt to complete studies necessary to submit an IND application for technology with U.S. FDA​.Itus Corp - ‍first payment from unit to Moffitt to be paid upon execution of agreement, and subsequent installments to be paid periodically thereafter​.  Full Article

ITUS Corp licenses CAR-T technology from Wistar Institute
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - ITUS Corp :ITUS Corporation licenses CAR-T technology from the Wistar Institute.Itus Corp - ‍executed exclusive worldwide license agreement with Wistar Institute for a Chimeric Antigen Receptor T-Cell (CAR-T) technology.ITUS Corp - has formed a subsidiary, Certainty Therapeutics Inc, to develop and commercialize innovative CAR-T technology​.  Full Article